AI-generated summary
The authors systematically reviewed nine studies (five human, four animal) on abdominal photobiomodulation and its effects on gut, metabolic, or brain outcomes. They report that human trials in Parkinson's and Alzheimer's disease, using 630 to 904 nm light, showed gains in mobility, balance, cognition, and olfaction, and that animal models showed cognitive and neuroprotective effects. The evidence is described as limited by small samples, heterogeneous dosimetry, and few sham-controlled human trials.
- Studies included
- 9
- Who or what was studied
- Human participants with Parkinson's or Alzheimer's disease, and animal models
- Wavelengths
- 630, 904 nm
- Limits stated in the abstract
- The abstract states that the evidence is limited by small samples, heterogeneous dosimetry, combined treatment sites, and few sham-controlled human trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background/Objectives
Bidirectional communication between the gut and brain is central to neurological and psychiatric health, and abdominal photobiomodulation (PBM) has emerged as a promising non-invasive way to modulate this axis by targeting intestinal mitochondria, epithelial integrity, and the microbiota. We systematically reviewed preclinical and clinical evidence on abdominal PBM, alone or in combined protocols, reporting microbiome, metabolic, or neurobehavioral outcomes.
Methods
Following PRISMA 2020 recommendations, we searched MEDLINE, Scopus, Web of Science, and ScienceDirect through May 2025 for animal and human studies applying PBM to the abdomen and reporting gut-related, metabolic, or brain-related outcomes.
Results
Nine studies met the eligibility criteria (five human, four animal). Human trials, mainly in Parkinson's and Alzheimer's disease, used 630-904 nm light and reported gains in mobility, balance, cognition, and olfaction; one trial also showed microbiota modulation with a decreased Firmicutes:Bacteroidetes ratio. Animal models revealed cognitive improvement, reduced neuroinflammation, dopaminergic neuroprotection, and microbial rebalancing. Mechanistic findings converged on enhanced mitochondrial bioenergetics, redox and anti-inflammatory signaling, vagal activation, and short-chain fatty acid-mediated effects.
Conclusions
Current evidence, though limited by small samples, heterogeneous dosimetry, combined treatment sites, and few sham-controlled human trials, suggests that abdominal PBM can influence the gut-brain axis through converging mitochondrial, immune, and microbial mechanisms. Adequately powered randomized trials with standardized dosimetry, validated mechanistic biomarkers, and integrative multi-omics analyses are needed to clarify causal pathways and optimize translational applications.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630-904 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Systematic review, Dosimetry, Neuroinflammation, Mitochondria, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.